Health

Inteleos 2026 Leadership Elections Accelerate Vision for Global Healthcare

ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Inteleos today announced its 2026 leadership elections that build on more than…

4 weeks ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

4 weeks ago

RadNet, Inc. to Present at the Raymond James 47th Annual Institutional Investors Conference on Tuesday, March 3rd, 2026

March 02, 2026 13:16 ET  | Source: RadNet, Inc. LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:…

1 month ago

Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam Repair System and REGENETEN Bioinductive Implant at AAOS 2026

Uniting the most advanced technologies for biomechanical repair and biological augmentation  Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today…

1 month ago

Pediatric Home Service Partners with Morgans to Expand Prescribed Pediatric Extended Care Services in Texas with New Center, Morgans Wonder Care

SAN ANTONIO, March 02, 2026 (GLOBE NEWSWIRE) -- Pediatric Home Service (PHS), a national provider of comprehensive pediatric healthcare, is…

1 month ago

Investor Education Webinar

The Future of Prostate Imaging: What do physicians want? March 01, 2026 17:57 ET  | Source: Telix Pharmaceuticals Limited MELBOURNE,…

1 month ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…

1 month ago

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026…

1 month ago

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

February 28, 2026 09:45 ET  | Source: Cogent Biosciences, Inc. Bezuclastinib mean TSS reduction deepens to –32.0 points at 48…

1 month ago